Skip to content
Search

Latest Stories

Top Stories

Trump Promised Healthcare Reform. Here’s How To Judge if He Delivers.

Trump Promised Healthcare Reform. Here’s How To Judge if He Delivers.
a doctor holding a stethoscope
Photo by Nappy on Unsplash

In 2016, Donald Trump promised to repeal the ACA and lower drug prices. In 2020, he claimed a plan was “two weeks away.” Now, more than 100 days back in office and facing mounting pressure to act on policy ahead of the 2026 midterms, Trump is once again pledging to fix American healthcare. Will this time be different?

Here are three tests that Americans can use to gauge whether the Trump administration succeeds or fails in delivering on its healthcare agenda.


Test No. 1: Have drug prices come down?

Americans pay two to four times more for prescription drugs than citizens in other wealthy nations. Today, nearly 30% of U.S. prescriptions go unfilled due to cost, leaving millions without the medications they need.

President Trump has repeatedly promised to change that. He recently stated, “The United States will no longer subsidize the healthcare of foreign countries and will no longer tolerate profiteering and price gouging.”

To support these commitments, the president signed an executive order titled “Delivering Most-Favored-Nation (MFN) Prescription Drug Pricing to American Patients.”

The order directs HHS to develop and communicate MFN price targets to pharmaceutical manufacturers, with the hope that they will voluntarily align U.S. drug prices with those in other developed nations. The idea is simple: If Germany and Canada pay $100 for a medication, Americans shouldn’t be charged $500. Should manufacturers fail to make significant progress toward these new targets, the administration has threatened to pursue additional measures, including the importation of drugs and tariffs.

Mandated price reductions would require congressional legislation—not just executive orders. The pharmaceutical industry is aware of this and is already pushing back, arguing that pricing reforms will hinder innovation and slow the development of lifesaving drugs.

But here’s the truth about drug “innovation”: According to a study by America’s Health Insurance Plans, seven out of 10 of the largest pharmaceutical companies spend more on sales and marketing than on research and development. If pharmaceutical companies want to invest more in R&D, a great start would be for them to require all nations to pay their fair share for identical medications.

If Congress fails to act on pharma pricing, the FDA could redefine “drug shortages” to include medications priced beyond the reach of most Americans. That change would enable compounding pharmacies to produce lower-cost alternatives just as they did recently with GLP-1 weight-loss injections.

However, if Americans continue paying more than twice as much as citizens in other wealthy nations, the administration will have failed this crucial test.

Test No. 2: Did food health quality improve?

Obesity has become a leading health threat in the United States, surpassing smoking and opioid addiction as a cause of death.

Since the 1980s, adult obesity rates have surged from 15% to over 40%, contributing significantly to chronic diseases, including type 2 diabetes, heart disease, and multiple types of cancers.

A major driver of this epidemic is the widespread consumption of ultra-processed foods: products high in added sugar, unhealthy fats, and artificial additives. These foods are engineered to be hyper-palatable and calorie-dense, promoting overconsumption and, in some cases, addictive eating behaviors.

In May, Health and Human Services Secretary Robert F. Kennedy Jr. led the release of the White House’s Make America Healthy Again (MAHA) report, which identifies ultra-processed foods, chemical exposures, lack of exercise, and excessive prescription drug use as primary contributors to America’s chronic disease epidemic. But success here will be measured by action, not rhetoric.

Thus, the administration will need to implement tangible policies such as:

· Front-of-package labeling. Require clear and aggressive labeling to inform consumers about the nutritional content of food products, using symbols to distinguish between healthy and unhealthy options.

· Taxation and subsidization. Impose taxes on unhealthy food items and use the revenue to subsidize healthier food options, especially for socio-economically disadvantaged populations.

· Regulation of food composition. Restrict the use of harmful additives and limit the total amount of fat and sugar included, particularly for foods aimed at kids.

Some of these policies have already been adopted in other nations and even in some U.S. states, showing they are achievable with political will. But if nothing changes, obesity will continue to rise, and the administration will fail.

Test No. 3: Are patients using generative AI to improve health?

The White House has signaled a strong commitment to using generative AI across various industries, including healthcare. Food and Drug Administration Commissioner Dr. Marty Makary has announced plans to integrate generative AI across all FDA centers by the end of this month.

But internal efficiency alone won’t improve the nation’s health. The administration will need to help develop and approve GenAI tools that expand clinical access, improve outcomes, and reduce costs. Ultimately, the real test will be whether the administration can turn GenAI into a tool for patients, not just paperwork.

Generative AI holds enormous promise. It can help patients better manage chronic diseases through continuous monitoring and by generating alerts when medication adjustments are needed. It can save lives by reducing the 400,000 annual deaths from misdiagnoses. It can also improve outcomes by personalizing treatment recommendations.

But realizing this potential will require major shifts. The NIH will need to fund the development of GenAI tools designed specifically for patient use, not just administrative tasks. The FDA will need to modernize outdated regulations that were built for static software, not constantly learning technologies. Most importantly, regulatory agencies must abandon the illusion of zero risk and evaluate new tools based on real-world performance, rather than theoretical perfection.

Ultimately, if generative AI technology remains confined to billing support and back-office automation, the opportunity to transform American healthcare will be lost. And the administration will have missed a vital opportunity to lower costs, save lives and ease clinician burnout.

Robert Pearl, the author of “ ChatGPT, MD,” teaches at both the Stanford University School of Medicine and the Stanford Graduate School of Business. He is a former CEO of The Permanente Medical Group.

Read More

Veterans’ Care at Risk Under Trump As Hundreds of Doctors and Nurses Reject Working at VA Hospitals
Photo illustration by Lisa Larson-Walker/ProPublica

Veterans’ Care at Risk Under Trump As Hundreds of Doctors and Nurses Reject Working at VA Hospitals

Veterans hospitals are struggling to replace hundreds of doctors and nurses who have left the health care system this year as the Trump administration pursues its pledge to simultaneously slash Department of Veterans Affairs staff and improve care.

Many job applicants are turning down offers, worried that the positions are not stable and uneasy with the overall direction of the agency, according to internal documents examined by ProPublica. The records show nearly 4 in 10 of the roughly 2,000 doctors offered jobs from January through March of this year turned them down. That is quadruple the rate of doctors rejecting offers during the same time period last year.

Keep ReadingShow less
Protecting the U.S. Press: The PRESS Act and What It Could Mean for Journalists

The Protect Reporters from Excessive State Suppression (PRESS) Act aims to fill the national shield law gap by providing two protections for journalists.

Getty Images, Manu Vega

Protecting the U.S. Press: The PRESS Act and What It Could Mean for Journalists

The First Amendment protects journalists during the news-gathering and publication processes. For example, under the First Amendment, reporters cannot be forced to report on an issue. However, the press is not entitled to different legal protections compared to a general member of the public under the First Amendment.

In the United States, there are protections for journalists beyond the First Amendment, including shield laws that protect journalists from pressure to reveal sources or information during news-gathering. 48 states and the District of Columbia have shield laws, but protections vary widely. There is currently no federal shield law. As of 2019, at least 22 journalists have been jailed in the U.S. for refusing to comply with requests to reveal sources of information. Seven other journalists have been jailed and fined for the same reason.

Keep ReadingShow less
Democrats Score Strategic Wins Amid Redistricting Battles

Democrat Donkey is winning arm wrestling match against Republican elephant

AI generated image

Democrats Score Strategic Wins Amid Redistricting Battles

Democrats are quietly building momentum in the 2025 election cycle, notching two key legislative flips in special elections and gaining ground in early polling ahead of the 2026 midterms. While the victories are modest in number, they signal a potential shift in voter sentiment — and a brewing backlash against Republican-led redistricting efforts.

Out of 40 special elections held across the United States so far in 2025, only two seats have changed party control — both flipping from Republican to Democrat.

Keep ReadingShow less
Policing or Occupation? Trump’s Militarizing America’s Cities Sets a Dangerous Precedent

A DC Metropolitan Police Department car is parked near a rally against the Trump Administration's federal takeover of the District of Columbia, outside of the AFL-CIO on August 11, 2025 in Washington, DC.

(Photo by Kevin Dietsch/Getty Images)

Policing or Occupation? Trump’s Militarizing America’s Cities Sets a Dangerous Precedent

President Trump announced the activation of hundreds of National Guard troops in Washington, D.C., along with the deployment of federal agents—including more than 100 from the FBI. This comes despite Justice Department data showing that violent crime in D.C. fell 35% from 2023 to 2024, reaching its lowest point in over three decades. These aren’t abstract numbers—they paint a picture of a city safer than it has been in a generation, with fewer homicides, assaults, and robberies than at any point since the early 1990s.

The contradiction could not be more glaring: the same president who, on January 6, 2021, stalled for hours as a violent uprising engulfed the Capitol is now rushing to “liberate” a city that—based on federal data—hasn’t been this safe in more than thirty years. Then, when democracy itself was under siege, urgency gave way to dithering; today, with no comparable emergency—only vague claims of lawlessness—he mobilizes troops for a mission that looks less like public safety and more like political theater. The disparity between those two moments is more than irony; it is a blueprint for how power can be selectively applied, depending on whose power is threatened.

Keep ReadingShow less